- Home
- FGF vs CGTX Comparison
FGF vs CGTX Comparison
Compare FGF & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- CGTX
- Stock Information
- Founded
- FGF 2012
- CGTX 2007
- Country
- FGF United States
- CGTX United States
- Employees
- FGF N/A
- CGTX N/A
- Industry
- FGF Property-Casualty Insurers
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- CGTX Health Care
- Exchange
- FGF Nasdaq
- CGTX Nasdaq
- Market Cap
- FGF 20.2M
- CGTX 23.1M
- IPO Year
- FGF N/A
- CGTX 2021
- Fundamental
- Price
- FGF $17.20
- CGTX $0.30
- Analyst Decision
- FGF
- CGTX Strong Buy
- Analyst Count
- FGF 0
- CGTX 5
- Target Price
- FGF N/A
- CGTX $6.13
- AVG Volume (30 Days)
- FGF 1.2K
- CGTX 803.7K
- Earning Date
- FGF 05-19-2025
- CGTX 05-07-2025
- Dividend Yield
- FGF N/A
- CGTX N/A
- EPS Growth
- FGF N/A
- CGTX N/A
- EPS
- FGF N/A
- CGTX N/A
- Revenue
- FGF $17,348,000.00
- CGTX N/A
- Revenue This Year
- FGF N/A
- CGTX N/A
- Revenue Next Year
- FGF N/A
- CGTX N/A
- P/E Ratio
- FGF N/A
- CGTX N/A
- Revenue Growth
- FGF 1.49
- CGTX N/A
- 52 Week Low
- FGF $14.21
- CGTX $0.31
- 52 Week High
- FGF $38.40
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- FGF 53.40
- CGTX 31.49
- Support Level
- FGF $16.27
- CGTX $0.40
- Resistance Level
- FGF $17.27
- CGTX $0.47
- Average True Range (ATR)
- FGF 0.30
- CGTX 0.04
- MACD
- FGF 0.20
- CGTX -0.01
- Stochastic Oscillator
- FGF 96.05
- CGTX 11.16
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.